We recently published a list of 10 Stocks Investors Dumped Fast. In this article, we are going to take a look at where ...

The findings support the clinical benefits of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) ...

Michele Johnson, partner with Latham & Watkins, is among the recipients of the The Recorder's 2025 Women Leaders in Tech Law, ...

We recently published a list of Was Jim Cramer Right About These 11 Stocks? In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other stocks ...

The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to ...

Sarepta Therapeutics (NasdaqGS:SRPT) saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year.

The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

The latest analyst rating for Sarepta Therapeutics (NASDAQ:SRPT) was provided by Scotiabank, and Sarepta Therapeutics upgraded their sector outperform rating. The last upgrade for Sarepta ...

Sarepta Therapeutics Inc.’s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease Duchenne muscular dystrophy has died of acute ...